Category: Life Sciences
United States Life Sciences
-
Local Anesthesia Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Lidocaine, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Probiotics Dietary Supplements
... at a CAGR of 5.8% over the analysis period 2024-2030. Capsules, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$4.2 Billion by the end of the ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Automated and Rapid Microbiological Tests
... Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. GC/CRT (Clinical), one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$1.3 Billion ... Read More
-
Multiple Myeloma Therapeutics
... at a CAGR of 14.5% over the analysis period 2024-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$37.6 Billion by the ... Read More
-
Radiopharmaceuticals
... 11.0% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$6.9 Billion by the end of the analysis period. Growth in ... Read More
-
Computer Aided Detection (CAD)
... 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Mammography, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$759.0 Million by the end ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis period. ... Read More
-
Microelectronic Medical Implants
... at a CAGR of 8.0% over the analysis period 2024-2030. Pacemakers & Defibrillators, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$22.7 Billion by the end ... Read More
-
Glaucoma Surgery Devices
... at a CAGR of 21.0% over the analysis period 2024-2030. Traditional, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$3.1 Billion by the end of the ... Read More
-
Medication Management Systems
... at a CAGR of 9.9% over the analysis period 2024-2030. Inventory Management Solutions, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$2.2 Billion by the end ... Read More
-
Multi-Parameter Patient Monitoring Equipment
... 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Portable, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$12.8 Billion by the end ... Read More
-
Vision Care
... CAGR of 2.3% over the analysis period 2024-2030. Glass Lens, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$54.6 Billion by the end of the analysis ... Read More
-
Human Papillomavirus (HPV) Testing
... 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Hospitals & Clinics End-Use, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$919.4 Million ... Read More
-
Hydroponics
... 14.2% over the analysis period 2024-2030. Tomatoes Crop, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth ... Read More
-
Herpes Marker Testing
... at a CAGR of 4.9% over the analysis period 2024-2030. Antibody / Antigen-Based Kits, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$332.9 Million by the ... Read More
-
Drug Screening
... CAGR of 16.7% over the analysis period 2024-2030. Drug Screening Products, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$16.7 Billion by the end of the ... Read More
-
Pectin
... 5.0% over the analysis period 2024-2030. Food & Beverage, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$904.0 Million by the end of the analysis period. ... Read More
-
Long-Term Care
... CAGR of 5.5% over the analysis period 2024-2030. Public Payer, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.1 Trillion by the end of the analysis ... Read More
-
Hair Transplant Services
... at a CAGR of 14.3% over the analysis period 2024-2030. Follicular Unit Extraction, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$14.3 Billion by the end ... Read More
-
Home Care Services
... at a CAGR of 7.3% over the analysis period 2024-2030. Maid Services, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$22.7 Billion by the end of ... Read More
-
Intrauterine Devices
... CAGR of 3.8% over the analysis period 2024-2030. Hormonal Progestogen-Releasing IUD, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$3.4 Billion by the end of the ... Read More
-
Analytical Laboratory Services
... at a CAGR of 9.0% over the analysis period 2024-2030. Bioanalytical Testing Service, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$273.4 Million by the end ... Read More
-
Box Office
... CAGR of 15.5% over the analysis period 2024-2030. Action / Adventure Genre, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$49.0 Billion by the end of ... Read More
-
Clot Management Devices
... at a CAGR of 4.6% over the analysis period 2024-2030. Percutaneous Thrombectomy Devices, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.1 Billion by the end ... Read More
Research Assistance
